Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors

Case inclusion criteria

• Patients with pathologically confirmed newly diagnosed solid tumors (such as melanoma, gastric cancer, colorectal cancer, etc.), or those with recent recurrence or suspected recurrence of previous solid tumors. Both male and female patients are eligible.
• Hematology, liver, and kidney function meeting the following criteria:

Hematology: WBC ≥ 4.0×10⁹/L or neutrophil count ≥ 1.5×10⁹/L, PLT ≥ 100×10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN.

Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for subjects with liver metastases), ALP ≤ 2.5 × ULN (if bone or liver metastases are present, ALP ≤ 4.5 × ULN); BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN.

• Expected survival ≥ 12 weeks.
• Good compliance with follow-up.
• Presence of at least one measurable target lesion according to RECIST 1.1 criteria.
• Female subjects must use effective contraception (effective contraception refers to sterilization, intrauterine hormone devices, condoms, contraceptive pills/agents, abstinence, or vasectomized partner) during the study and for 6 months after the study ends; male subjects must agree to use contraception during the study and for 6 months after the study ends.
• Subjects must fully understand and voluntarily participate in this trial, and sign the Informed Consent Form.

Case exclusion criteria

• Severe liver and kidney dysfunction.
• Women preparing for pregnancy, pregnant, or breastfeeding.
• Inability to lie flat for half an hour.
• Inability to provide informed consent.
• Suffering from claustrophobia or other psychiatric disorders.
• Known allergy to the investigational drug or its excipients.
• Other situations deemed unsuitable for trial participation by the researchers.